Literature DB >> 1546139

Influence of moclobemide on ibuprofen-induced faecal blood loss.

T W Güntert1, M Schmitt, J Dingemanse, J H Jonkman.   

Abstract

In a pharmacological screen on drug-drug interactions performed in laboratory animals moclobemide potentiated at high doses the antiphlogistic/anti-inflammatory activity of ibuprofen. Therefore, a study was undertaken to determine in healthy volunteers the faecal blood loss induced by multiple doses of ibuprofen (600 mg t.i.d.) in presence and absence of steady-state concentrations of concomitantly administered moclobemide (150 mg t.i.d.). The results show that multiple doses of moclobemide do not change faecal blood loss induced by ibuprofen. Furthermore, no clinically relevant pharmacokinetic interaction between the two drugs studied was detected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546139     DOI: 10.1007/bf02246233

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  4 in total

1.  The use of the isotope 51Cr as a label for red cells.

Authors:  P L MOLLISON; N VEALL
Journal:  Br J Haematol       Date:  1955-01       Impact factor: 6.998

2.  Studies of gastrointestinal blood loss during ibuprofen therapy.

Authors:  M Thompson; M Anderson
Journal:  Rheumatol Phys Med       Date:  1970

3.  Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males.

Authors:  I L Salom; G Jacob; N Jallad; C A Perdomo; J F Mullane; D Weidler
Journal:  J Clin Pharmacol       Date:  1984 May-Jun       Impact factor: 3.126

4.  Gastro-intestinal blood loss during administration of indoprofen, aspirin and ibuprofen.

Authors:  G B Porro; G Corvi; L M Fuccella; G C Goldaniga; G Valzelli
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

  4 in total
  1 in total

Review 1.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.